Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +48.99%
#3 ADO Protocol ADO Protocol +38.81%
#4 Pons Pons +35.91%
#5 Prom Prom +34.77%
#6 TENDIES TENDIES +33.49%
#7 StonkBroker StonkBroker +29.41%
#8 Collector Crypt Collector Crypt +27.84%
#9 龙虾 (Lobster) 龙虾 (Lobster) +21.48%
#10 Cysic Cysic +20.11%
Coin of the day
GEKKO GEKKO
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Classificação em ações #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Preço da ação
$1.72
Última sincronização: 2026-08-28
Valor de mercado
$981.92M
Variação (1 dia)
-1.68%
Variação (1 ano)
-41.83%
País
CN
Negociar CARsgen Therapeutics Holdings Limited (2171)

Categoria

Healthcare
Histórico de dividendos de CARsgen Therapeutics Holdings Limited (2171)
CARsgen Therapeutics Holdings Limited (símbolo da ação: 2171) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de CARsgen Therapeutics Holdings Limited (2171) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH